ANTIPLATELET THERAPY OF ACUTE CORONARY SYNDROME: CURRENT CAPAB ILITIES
Dual antiplatelet therapy (acetylsalicylic acid and platelet P2Y12 receptor antagonist) is a standard component of treatment of any type of acute coronary syndrome, independently of perfusion and the chosen treatment strategy. Due to certain limitations of clopidogrel as the 2nd component of dual an...
Saved in:
| Main Authors: | E. V. Konstantinova, М. Yu. Gilyarov, N. А. Shostak, D. A. Anichkov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2018-07-01
|
| Series: | Klinicist |
| Subjects: | |
| Online Access: | https://klinitsist.abvpress.ru/Klin/article/view/335 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01) -
Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
by: T. M. Uskach, et al.
Published: (2020-12-01) -
Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk
by: O. V. Averkov
Published: (2021-02-01) -
Double antiplatelet therapy in patients with acute coronary syndrome
by: A. V. Rodionov, et al.
Published: (2011-10-01) -
The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention
by: A. S. Tereshchenko, et al.
Published: (2019-05-01)